Transgene Cash Per Share vs. Price To Earning
| TNG Stock | EUR 0.73 0.01 1.35% |
For Transgene profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Transgene to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Transgene SA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Transgene's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Transgene SA over time as well as its relative position and ranking within its peers.
Transgene |
Transgene SA Price To Earning vs. Cash Per Share Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Transgene's current stock value. Our valuation model uses many indicators to compare Transgene value to that of its competitors to determine the firm's financial worth. Transgene SA is currently regarded as top stock in cash per share category among its peers. It also is currently regarded as top stock in price to earning category among its peers reporting about 66.96 of Price To Earning per Cash Per Share. Comparative valuation analysis is a catch-all model that can be used if you cannot value Transgene by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Transgene's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Transgene Price To Earning vs. Cash Per Share
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Transgene |
| = | 0.27 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Transgene |
| = | 18.08 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Transgene Price To Earning Comparison
Transgene is currently under evaluation in price to earning category among its peers.
Transgene Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Transgene, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Transgene will eventually generate negative long term returns. The profitability progress is the general direction of Transgene's change in net profit over the period of time. It can combine multiple indicators of Transgene, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. TRANSGENE operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 132 people.
Transgene Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Transgene. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Transgene position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Transgene's important profitability drivers and their relationship over time.
Use Transgene in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Transgene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Transgene will appreciate offsetting losses from the drop in the long position's value.Transgene Pair Trading
Transgene SA Pair Trading Analysis
The ability to find closely correlated positions to Transgene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Transgene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Transgene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Transgene SA to buy it.
The correlation of Transgene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Transgene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Transgene SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Transgene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Transgene position
In addition to having Transgene in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investing Thematic Idea Now
Investing
Companies involved in money management and investment banking services. The Investing theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Transgene Stock
To fully project Transgene's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Transgene SA at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Transgene's income statement, its balance sheet, and the statement of cash flows.